HAI DANG: Open Payments
NPI 1437589090 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 13 payments from 7 companies in 2025. Trend: 2023 $360 · 2024 $303 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $332 |
| Astellas Pharma US Inc | 3 | $95 |
| Syndax Pharmaceuticals, Inc. | 2 | $64 |
| Incyte Corporation | 2 | $58 |
| ABBVIE INC. | 1 | $33 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Lilly USA, LLC | 1 | $29 |
Products named: Vemlidy, Cresemba, EPKINLY, CALQUENCE, Xospata, JAKAFI, JAYPIRCA, NIKTIMVO.
Industry payments across TX — which companies pay providers there.
